Vendor Intelligence Report: ZZQ Peptides

Executive summary

ZZQ Peptides is a new-looking China-listed storefront with an uneven lab record and a much thinner identity trail than its manufacturer branding suggests. Across 43 Finnrick lab tests, the record is 28 pass / 14 fail for a 65% overall pass rate. The spread matters more than the headline: GHK-Cu is the most defensible tested line, Tesamorelin is the clearest avoid signal, and Retatrutide’s better aggregate score is offset by a documented identity/fill-accuracy warning. Tirzepatide sits in the inconsistent middle, and the report’s methodology-divergence view shows ratings falling as grading tightens.

The web-forensics file is not a simple young-vendor note. Domain and archive records conflict with the site’s 2013-style vintage, the listed email domain ties back to a Shijiazhuang IT-services company, and the public contact stack mixes a Shanghai address with a Hong Kong mobile number. The About page leans on fuwucms boilerplate, rendered/stock facility imagery, and placeholder-style social implementation rather than manufacturer-specific evidence.

ZZQ also sits inside a broader template-network pattern. A related peptide storefront appears on the same hosting lane, copied manufacturer text shows up across multiple peptide domains, and the catalog blends GLP-1 peptides with anabolic-steroid products. One steroid page displays the wrong product image, a small-looking web error that becomes material when buyers are trying to identify gray-market vials and tablets.

Inside the full report:

• Product-specific Finnrick lab interpretation, including pass/fail breakdowns, score trend charts, and methodology-divergence charts for all 4 tested products
• WHOIS and Wayback timeline for zzqpeptide.com, xtxinyao.cn, and the linked EHZ Peptide storefront
• Contact and address verification showing the Shanghai listing, Hong Kong mobile number, and IT-services email-domain trail
• Reverse-IP, fuwucms CDN, and copied-text analysis across the sister-brand network
• Catalog audit covering GLP-1 products, Schedule III anabolic-steroid listings, and the Superdrol image mismatch
• Batch-traceability review, regulatory freight context, re-verification anchors, and open leads

Risk assessment

• Corporate-identity and manufacturer-claim risk — high: The listed contact email domain is registered to an IT-services company, the claimed 2013 vintage conflicts with a 2025 domain registration, and no operating peptide manufacturer was verified.
• Template-network and channel-verification risk — high: ZZQ uses fuwucms template assets and copied manufacturer text shared across multiple peptide storefronts, while providing no official-channel list, authorized-reseller list, or verifiable batch-COA system.
• Controlled-substance catalog and product-identification risk — high: The catalog includes Superdrol and testosterone enanthate products identified as U.S. Schedule III anabolic steroids, and the Superdrol page displayed a testosterone-vial image.
• Retatrutide identity and dose-reliability risk — high: Retatrutide rates 79.06% in the supplied Finnrick figures, but the product record includes a documented identity failure and severe fill-accuracy events.
• Tesamorelin quality-reliability risk — high: Tesamorelin is ZZQ’s weakest tested product at 42.97%, with 2 pass and 3 fail across 5 tests.
• Tirzepatide consistency risk — medium: Tirzepatide rates 65.41%, with 10 pass and 7 fail across 17 tests, indicating materially inconsistent product performance.
• Batch-traceability risk — high: Finnrick product records referenced cap colors, dates, reused-looking identifiers, or no batch ID, leaving buyers without pharmaceutical-grade recall traceability.